Journal of Diabetes and Its Complications
Volume 21, Issue 3 , Pages 196-204 , May 2007

Comparison of insulin glargine and NPH insulin in the treatment of type 2 diabetes: a review of clinical studies

  • William Duckworth

      Affiliations

    • Carl T. Hayden VA Medical Center, Arizona State University, Phoenix, AZ, USA
    • Corresponding Author InformationCorresponding author. Carl T. Hayden VA Medical Center, Mailcode Cs-111e, 650 E. Indian School Road, Phoenix, AZ 85012, USA. Tel.: +1 602 277 5551x6802.
    • ,
  • Stephen N. Davis

      Affiliations

    • Vanderbilt University Nashville, Nashville, TN, USA

Received 7 July 2006 ,Accepted 13 December 2006.

References 

  1. American College of Endocrinology . Consensus statement on guidelines for glycemic control. Endocrine Practice. 2002;8(Suppl 1):5–11
  2. American Diabetes Association. Economic costs of diabetes in the U.S. in 2002. Diabetes Care. 2003;26:917–932
  3. American Diabetes Association. National diabetes fact sheet. Prevalence of total diabetes in the United States, all ages — United States, 2002. Available at: http://www.diabetes.org/diabetes-statistics/prevalence.jsp2002;
  4. American Diabetes Association . Standards of medical care in diabetes. Diabetes Care. 2005;28(Suppl 1):S4–S36
  5. Coutinho M, Gerstein HC, Wang Y, Yusuf S. The relationship between glucose and incident cardiovascular events: a metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care. 1999;22:233–240
  6. Cryer PE. Hypoglycaemia: the limiting factor in the glycaemic management of type I and type II diabetes. Diabetologia. 2002;45:937–948
  7. Davies M, Storms F, Shutler S, Bianchi-Biscay M, Gomis R. Improvement of glycemic control in subjects with poorly controlled type 2 diabetes: comparison of two treatment algorithms using insulin glargine. Diabetes Care. 2005;28:1282–1288
  8. DeFronzo RA. Pharmacologic therapy for type 2 diabetes mellitus. Annals of Internal Medicine. 1999;131:281–303
  9. DeWitt DE, Hirsch IB. Outpatient insulin therapy in type 1 and type 2 diabetes mellitus: scientific review. Journal of the American Medical Association. 2003;289:2254–2264
  10. Fonseca V, Bell DS, Berger S, Thomson S, Mecca TE. A comparison of bedtime insulin glargine with bedtime neutral protamine Hagedorn insulin in patients with type 2 diabetes: subgroup analysis of patients taking once-daily insulin in a multicenter, randomized, parallel group study. American Journal of the Medical Sciences. 2004;328:274–280
  11. Fritsche A, Schweitzer MA, Häring H-U. Glimepiride combined with morning insulin glargine, bedtime neutral protamine Hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes: a randomized, controlled trial. Annals of Internal Medicine. 2003;138:952–959
  12. Genuth S. Insulin use in NIDDM. Diabetes Care. 1990;13:1240–1264
  13. Gerich JE. Contributions of insulin-resistance and insulin-secretory defects to the pathogenesis of type 2 diabetes mellitus. Mayo Clinic Proceedings. 2003;78:447–456
  14. Hayward RA, Manning WG, Kaplan SH, Wagner EH, Greenfield S. Starting insulin therapy in patients with type 2 diabetes: effectiveness, complications, and resource utilization. Journal of the American Medical Association. 1997;278:1663–1669
  15. Hirsch IB. Insulin analogues. New England Journal of Medicine. 2005;352:174–183
  16. HOE 901/2004 Study Investigators Group. Safety and efficacy of insulin glargine (HOE 901) versus NPH insulin in combination with oral treatment in Type 2 diabetic patients. Diabetic Medicine. 2003;20:545–551
  17. Hunt LM, Valenzuela MA, Pugh JA. NIDDM patients' fears and hopes about insulin therapy: the basis of patient reluctance. Diabetes Care. 1997;20:292–298
  18. Kennedy L, Herman WH, Strange P, Harris A, for the GOAL A1C Team . Impact of active versus usual algorithmic titration of basal insulin and po1nt-of-care versus laboratory measurement of HbA1C on glycemic control in patients with type 2 diabetes: The Glycemic Optimization with Algorithms and Labs at Po1nt of Care (GOAL A1C) trial. Diabetes Care. 2006;29:1–8
  19. Khaw K-T, Wareham N, Bingham S, Luben R, Welch A, Day N. Association of hemoglobin A1C with cardiovascular disease and mortality in adults: the European Prospective Investigation into Cancer in Norfolk. Annals of Internal Medicine. 2004;141:413–420
  20. Khaw K-T, Wareham N, Luben R, Bingham S, Oakes S, Welch A, et al. Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of European Prospective Investigation of Cancer and Nutrition (EPIC-Norfolk). British Medical Journal. 2001;322:1–6
  21. Lantus [package insert]. Kansas City, MO: Aventis Pharmaceuticals Inc; 2004;
  22. Lepore M, Pampanelli S, Fanelli C, Porcellati F, Bartocci L, Di Vincenzo A, et al. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes. 2000;49:2142–2148
  23. Massi Benedetti M, Humburg E, Dressler A, Ziemen M. A one-year, randomised, multicentre trial comparing insulin glargine with NPH insulin in combination with oral agents in patients with type 2 diabetes. Hormone and Metabolic Research. 2003;35:189–196
  24. Polonsky WH, Jackson RA. What's so tough about taking insulin? Addressing the problem of psychological insulin resistance in type 2 diabetes. Clinical Diabetes. 2004;22:147–150
  25. Raslova K, Bogoev M, Raz I, Leth G, Gall MA, Hancu N. Insulin detemir and insulin aspart: a promising basal-bolus regimen for type 2 diabetes. Diabetes Research and Clinical Practice. 2004;66:193–201
  26. Resnick HE, Foster GL, Bardsley J, Ratner RE. Achievement of American Diabetes Association Clinical Practice Recommendations among U.S. adults with diabetes, 1999–2002: the National Health and Nutrition Examination Survey. Diabetes Care. 2006;29:531–537
  27. Riddle MC. Evening insulin strategy. Diabetes Care. 1990;13:676–686
  28. Riddle MC, Rosenstock J, Gerich J, the Insulin Glargine Study Investigators . The Treat-to-Target Trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care. 2003;26:3080–3086
  29. Rosenstock J, Schwartz SL, Clark CMJ, Park GD, Donley DW, Edwards MB. Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin. Diabetes Care. 2001;24:631–636
  30. Rossetti L. Glucose toxicity: the implications of hyperglycemia in the pathophysiology of diabetes mellitus. Clinical and Investigative Medicine. 1995;18:255–260
  31. Ryysy L, Yki-Järvinen H, Hänninen J. Simplifying treat to target — the LANMET study. In: Program and abstract of the 40th European Association for the Study of Diabetes Annual Meeting, September 5–9, Munich, Germany. Abstract 749. 2004;
  32. Saydah SH, Fradkin J, Cowie CC. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. Journal of the American Medical Association. 2004;291:335–342
  33. Starke AAR, Heinemann L, Hohmann A, Berger M. The action profiles of human NPH insulin preparations. Diabetic Medicine. 1989;6:239–244
  34. Stratton IM, Adler AI, Neil HAW, et al. UK Prospective Diabetes Study Group Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. British Medical Journal. 2000;321:405–412
  35. Turner RC, Cull CA, Frighi V, Holman RR the U.K. Prospective Diabetes Study Group. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). Journal of the American Medical Association. 1999;281:2005–2012
  36. U.K. Prospective Diabetes Study Group. U.K. Prospective Diabetes Study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes. 1995;44:1249–1258
  37. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352:854–865
  38. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837–853
  39. Utzschneider KM, Carr DB, Barsness SM, Kahn SE, Schwartz RS. Diet-induced weight loss is associated with an improvement in β-cell function in older men. The Journal of Clinical Endocrinology & Metabolism. 2004;89:2704–2710
  40. Witthaus E, Stewart J, Bradley C. Treatment satisfaction and psychological well-being with insulin glargine compared with NPH in patients with type 1 diabetes. Diabetic Medicine. 2001;18:619–625
  41. Wright A, Burden ACF, Paisey RB, Cull CA, Holman RR. Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57). Diabetes Care. 2002;25:330–336
  42. Yale J-F, Valiquett TR, Ghazzi MN, Owens-Grillo JK, Whitcomb RW, Foyt HL. The effect of a thiazolidinedione drug, troglitazone, on glycemia in patients with type 2 diabetes mellitus poorly controlled with sulfonylurea and metformin. A multicenter, randomized, double-blind, placebo-controlled trial. Annals of Internal Medicine. 2001;134:737–745
  43. Yki-Järvinen H. Combination therapy with insulin and oral agents: optimizing glycemic control in patients with type 2 diabetes mellitus. Diabetes/Metabolism Research and Reviews. 2002;18(Suppl 3):S77–S81
  44. Yki-Järvinen H, Dressler A, Ziemen M. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. Diabetes Care. 2000;23:1130–1136

☆ Support: This manuscript was supported by sanofi-aventis U.S. Many of the studies reported within this manuscript have also been supported by sanofi-aventis US.

☆☆ Conflict of interest statement: Dr. William Duckworth has received research grant support from Novo Nordisk Pharmaceuticals, Inc., sanofi-aventis U.S., Roche Diagnostics, and Kos Pharmaceuticals, Inc.; has been a consultant for Novo Nordisk Pharmaceuticals, Inc., and sanofi-aventis U.S.; and has been involved with the Bristol-Myers Squibb speakers bureau. Dr. Stephen Davis has received grant support from sanofi-aventis U.S. and Eli Lilly and Company.

★ Disclaimer: Reference herein to any specific commercial products, process, or service by trade name, trademark, manufacturer, or otherwise, does not necessarily constitute or imply its endorsement, recommendation, or favoring by the United States Government. The views and opinions of authors expressed herein do not necessarily state or reflect those of the United States Government, and shall not be used for advertising or product endorsement purposes.

PII: S1056-8727(07)00007-4

doi: 10.1016/j.jdiacomp.2007.01.001

Journal of Diabetes and Its Complications
Volume 21, Issue 3 , Pages 196-204 , May 2007

Article Tools

* Image Usage & Resolution